Archive for 29 marzo 2010

Novartis – People (2009)


Board of Directors

Daniel Vasella, M.D.
– Chief Executive Officer and Executive member of the Board of Directors since 1996; Chairman of the Board of Directors since 1999.
– Member of Bilderberg Group (1998, 1999, 2003, 2004, 2005, 2008).
– Board of Directors of Pepsico Inc., New York, and Alcon Inc., Switzerland.
– Global Health Program Advisory Panel of the Bill & Melinda Gates Foundation.
– Foreign honorary member of the American Academy of Arts and Sciences, the International Business Leaders Advisory Council for the Mayor of Shanghai, and the International Board of Governors of the Peres Center for Peace in Israel.
– CEO of Sandoz Pharmaceuticals Corporation (1988-1996).
– Honored with the Harvard Business School‘s Alumni Achievement Award and Appeal of Conscience Award, the AJ Congress Humanitarian Award, the Ordem Nacional do Cruzeiro do Sul (Brazil), and rank of Chevalier in the Ordre national de la Légion d’honneur (France).
– Honorary doctorate by the University of Basel.
– M.D. from the University of Bern, Switzerland (1979).

Ulrich Lehner, Ph.D.
– Vice Chairman, Lead Director and Chairman of the Corporate Governance and Nomination Committee; Audit and Compliance Committee, the Chairman’s Committee and the Compensation Committee; Appointed as Audit Committee Financial Expert; Board of Directors since 2002.
– Chairman of the supervisory board of Deutsche Telekom AG.
– Supervisory board of E.ON AG, of Thyssen Krupp AG, of HSBC Trinkaus & Burkhardt KGaA and of Porsche Automobil Holding SE, all in Germany.
– Shareholders’ committee of Henkel AG & Co. KGaA and Oetker KG (Germany).
– Auditor with KPMG Deutsche Treuhand-Gesellschaft AG in Duesseldorf (1975-1981).
Krupp GmbH in Germany (1983-1986).
– Heads the Management Holding Henkel Asia-Pacific Ltd., Hong Kong (1991-1994)
– Finance Director, Executive Vice President, Finance/Logistics (1995-2000) and Chairman of the Management Board (2000-2008) of Henkel KGaA.
– Graduated in business administration and mechanical engineering from the Darmstadt University of Technology (1975).

Hans-Joerg Rudloff
– Vice Chairman and Chairman of the Compensation Committee; Chairman’s Committee and the Audit and Compliance Committee; Audit Committee Financial Expert; Board of Directors since 1996.
– Boards of Directors of the Thyssen-Bornemisza Group, Monaco, and RBC, Russia.
– Chairman of the International Capital Markets Association, Switzerland, since 2005.
– Board of Directors and Chairman of the audit committee of Rosneft, a Russian state-controlled oil company, since 2006.
– Chairman of the Board of Directors of Bluebay Asset Management Ltd., United Kingdom, and the Marcuard Group, Switzerland.
– Board of directors of New World Resources B.V., Netherlands.
– Advisory boards of Landeskreditbank Baden-Wuerttemberg and Energie Baden-Wuerttemberg, both in Germany.
Credit Suisse, Geneva (1965).
– New York-based investment banking firm of Kidder Peabody Inc. (1968).
– Chairman of Kidder Peabody International.
– Board of Directors of Kidder Peabody Inc., United States (1978).
– Joined (1980); Vice Chairman (1983); Chairman and CEO (1989) at Credit Suisse First Boston, Switzerland.
– Executive board of Credit Suisse in Zurich, in charge of all securities and capital-market departments, (1986-1990).
– Chairman of MCBBL in Luxembourg (1994-1998).
– Board of Directors of Sandoz AG since 1994.
– Chairman of Barclays Capital (UK) since 1998.
– Economics at the University of Bern.

William Brody, M.D., Ph.D.
– President of the Johns Hopkins University in Baltimore, U.S., until the end of 2008.
– President-designate of the Salk Institute in La Jolla, U.S.
– Professor for Radiology and Electrical Engineering at Stanford University and Professor and Director of the Department of Radiology at the Johns Hopkins University.
– Boards of Directors of IBM, AEGON U.S. and Mercantile Bankshares Corporation.
– B.S. and M.S. degrees in electrical engineering from the Massachusetts Institute of Technology.
– M.D. and Ph.D. at Stanford University.

Srikant Datar, Ph.D.
– Board of Directors since 2003.
– Chairman of the Audit and Compliance Committee and a member of the Compensation Committee.
– Appointed him as Audit Committee Financial Expert.
– Board of Directors of ICF International Inc., Virginia, and KPIT Cummins Infosystems Ltd., India.
– Arthur Lowes Dickinson Professorship at Harvard University.
– Chartered Accountant and two master’s degrees and a Ph.D. from Stanford University.
– Professor at the Carnegie Mellon University, Stanford University and Harvard University.
– Senior Associate Dean at the Graduate School of Business Administration of Harvard.
– Advisor and work with numerous renowned firms such as General Motors, Mellon Bank and Morgan Stanley in research, development and training.
– Graduated in mathematics and economics from the University of Bombay (1973).

Ann Fudge
– Board of Directors since 2008.
– Member of the Corporate Governance and Nomination Committee.
– Board of Directors of General Electric, Connecticut.
– Board of Overseers of Harvard University.
– Trustee of the Rockefeller Foundation and of Morehouse College.
– Chair of the U.S. Programs Advisory Panel of the Gates Foundation.
– Former Chairman and CEO of Young & Rubicam Brands.
– President of the Beverages, Desserts and Post Division of Kraft Foods.
– B.A. from Simmons College and M.B.A. from Harvard University Graduate School of Business.

Alexandre F. Jetzer
– – Head of International Coordination, Legal & Taxes and a member of the Executive Committee (1996-1999); Board of Directors since 1996.
– Member of the supervisory board of Compagnie Financière Michelin, Switzerland, and of the board of the Lucerne Festival Foundation, Switzerland.
– Member of the International Advisory Panel on Biotechnology Strategy of the Prime Minister of Malaysia, a member of the Investment Advisory Council of the Prime Minister of Turkey and economic advisor to the Governor of Guangdong Province, China.
– Member of the Development Committee of the Neuroscience Center of the University of Zurich, Switzerland.
– General Secretary of the Swiss Federation of Commerce and Industry (1967-1980).
– Joined Sandoz in 1980, Chief Financial Officer in 1981, and Head of Management Resources and International Coordination in 1990.
– Chairman and Chief Executive Officer of Sandoz Pharmaceuticals Corporation in East Hanover, New Jersey, and President and CEO of Sandoz Corporation in New York (1995-1996).
– Graduated with master’s degrees in law and economics from the University of Neuchâtel, Switzerland, and licensed attorney.

Pierre Landolt
– Board of Directors since 1996.
– Member of the Corporate Governance and Nomination Committee.
– Chairman of the Sandoz Family Foundation and Director of Syngenta AG.
– Partner with unlimited liabilities of the private bank Landolt & Cie.
– President of the Instituto Fazenda Tamanduá, the Instituto Estrela de Fomento ao Microcrédito, AxialPar Ltda and Moco Agropecuaria Ltda, in Brazil.
– Chairman of Emasan AG and Vaucher Manufacture Fleurier S.A. and Vice-Chairman of Parmigiani Fleurier S.A., in Switzerland.
– Director of EcoCarbone S.A. and Amazentis S.A..
– Formerly Chairman of the CITCO Group (1995-2005).
– Vice-Chairman of the Montreux Jazz Festival Foundation.
Sandoz Brazil S.A. (1974-1976).
– Associate and Chairman of AxialPar Ltda, Brazil, an investment company focused on sustainable development, with investments in fish farming, soybean for human consumption and organic vegetable, since 1997.
– Co-founded EcoCarbone S.A., France, a company active in the design and development of carbon-sequestration processes in Asia, Africa, South America and Europe (2000).
– Co-founded Amazentis S.A., start-up company active in the convergence space of medication and nutrition (2007).
– President of the Sandoz Family Foundation since 1994 and oversees the development of the foundation in several investment fields, inter alia hotel, watch making and telecommunications.
– Bachelor degree in law from the University of Paris-Assas.

Andreas von Planta, Ph.D.
– Board of Directors since 2006.
– Member of the Audit and Compliance Committee and the Corporate Governance and Nomination Committee.
– Vice Chairman of Holcim Ltd. and of the Schweizerische National-Versicherungs-Gesellschaft AG, both in Switzerland.
– Member of the boards of various Swiss subsidiaries of foreign companies and other non-listed Swiss companies.
– Member of the board of editors of the Swiss Review of Business Law and former Chairman of the Geneva Association of Business Law.
– Chairman of the regulatory board of the SIX Swiss Exchange AG.
– Joined (1983); Partner (1988) at Lenz & Staehelin.
– Ph.D. degree from the University of Basel and LL.M. from Columbia University School of Law, New York.

Dr. Ing. Wendelin Wiedeking
– Board of Directors since 2003.
– Chairman of the executive board of Porsche Automobil Holding SE and Porsche AG, Germany.
– Supervisory board of Volkswagen AG and AUDI AG, Germany.
– Graduated in mechanical engineering (1978).
– Scientific assistant in the Machine Tool Laboratory of the Rhine-Westphalian College of Advanced Technology in Aachen, Germany.
– Director’s Assistant in the Production and Materials Management area of Porsche AG in Stuttgart-Zuffenhausen (1983).
– Division Manager in Wiesbaden (1988) at Glyco Metall-Werke KG; Chief Executive Officer (1990); Chairman of the Board of Management of Glyco AG.
– Production Director (1991); spokesman of the executive board and CEO (1992); Chairman (1993) of Porsche AG.

Marjorie M. Yang
– Member of the Compensation Committee; Board of Directors since 2008.
– Chairman of the Esquel Group, Hong Kong, since 1995.
– Boards of Directors of Swire Pacific Ltd., CLP Holdings and The Hong Kong and Shanghai Banking Corporation Ltd., Hong Kong.
– Member of the National Committee of the Chinese People’s Political Consultative Conference, Chairman of the Textile and Clothing Sector Committee, Vice Chairman of the China Association of Enterprises with Foreign Investment and a member of the M.I.T. Corporation.
– Board of Dean’s Advisors of Harvard Business School.
– Associate in Corporate Finance, Mergers and Acquisitions with the First Boston Corporation in New York (1976-1978).
– B.S. in mathematics from Massachusetts Institute of Technology and M.B.A. from Harvard Business School.

Rolf M. Zinkernagel, M.D.
– Member of the Corporate Governance and Nomination Committee; Board of Directors since 1999.
– Member of the Swiss Society of Allergy and Immunology and the American Associations of Immunologists and of Pathologists.
– Member of the Advisory Council of BMS Singapore.
– Past President of the executive board of the International Union of Immunological Societies.
– Member of the scientific advisory boards of Bio-Alliance AG, Germany; Aravis General Partner Ltd., Cayman Islands; Telormedix, Switzerland; Esbatech, Switzerland; Novimmune, Switzerland; Cancevir, Switzerland; xbiotech, Canada; Nuvo Research Inc., Canada; ImVision, Germany; MannKind, California; and Laboratoire Koch, Switzerland.
– Science consultant to Chilka Ltd., Grand Cayman; Ganymed, Germany; and Zhen-Ao Group, China.
– Member of the Advisory Panel of Swiss Re, Switzerland.
– Professor and Director of the Institute of Experimental Immunology at the University of Zurich (1992-2008).
Nobel Prize for Medicine (1996).
– M.D. from the University of Basel (1970).

Executive Committee

Raymund Breu, Ph.D.
– Chief Financial Officer and Member of the Executive Committee since 1996.
– Joined the Treasury Department of the Sandoz Group (1975); Head of Finance for the Sandoz affiliates in the U.K. (1982); Chief Financial Officer of Sandoz Corporation in New York, where responsible for all Finance activities in the U.S. (1985); Group Treasurer of Sandoz Ltd., Basel, Switzerland (1990); Head of Group Finance and Member of the Sandoz Executive Board (1993).
– Board of Directors of Swiss Re and the Swiss takeover commission.
– Ph.D. in mathematics from the Swiss Federal Institute of Technology in Zurich, Switzerland.

Juergen Brokatzky-Geiger, Ph.D.
– Head of Human Resources since 2003 and Member of the Executive Committee since 2005.
– Laboratory Head in the Pharmaceuticals Division of Ciba-Geigy Ltd. (1983); Positions of increasing responsibility in Research and Development including Group Leader of Process R&D; Head of Process R&D; Head of Process Development and Pilot Plant Operations; Integration Officer of Technical Operations during the merger (1996); Head of Chemical and Analytical Development and Global Head of Technical R&D (1999-2003).
– Ph.D. in chemistry from the University of Freiburg, Germany (1982).

Mark C. Fishman, M.D.
– From the NIBR headquarters in Cambridge, Massachusetts, leads the worldwide discovery research activities in Europe, the United States and China; President of Institutes for BioMedical Research and Member of the Executive Committee since 2002.
– Chief of Cardiology and Director of the Cardiovascular Research Center at Massachusetts General Hospital in Boston.
– Professor of Medicine at Harvard Medical School.
– Serves on several editorial boards and has worked with national policy and scientific committees, including those of the U.S. National Institutes of Health and the Wellcome Trust.
– Internal medicine residency, chief residency and cardiology
training at Massachusetts General Hospital.
– Pre-eminent in the fields of genetic and molecular cardiology, with a principal focus on embryonic heart development.
– Best known for his studies in developmental genetics, in particular his role in introducing the zebra fish as a model for gene discovery.
– B.A. from Yale College (1972) and M.D. from Harvard Medical School (1976).
– Member of the Institute of Medicine of the National Academies (US) and Fellow of the American Academy of Arts and Sciences.

Joseph Jimenez
– CEO of the Pharmaceuticals Division and member of the Executive Committee since 2007.
– Began his career at The Clorox Company, California.
– President of two operating divisions at ConAgra, Nebraska.
– President and Chief Executive Officer of the North America business of the H.J. Heinz Company, Pennsylvania.
– President and Chief Executive Officer of Heinz in Europe (2002-2006).
– Non-executive director of AstraZeneca plc, United Kingdom, (2002-2007).
– Advisor for the private equity organization Blackstone Group, New York.
– B.A. from Stanford University (1982) and M.B.A. from the University of California, Berkeley (1984).

Joerg Reinhardt, Ph.D.
– Head of Preclinical Development and Project Management (1996); Head of Pharmaceutical Development (1999); Head of the Vaccines and Diagnostics Division (2006-2008); Chief Operating Officer since 2008; Member of the Executive Committee since 2007.
– Positions of increasing responsibility in Research and Development (1982); Head of Development (1994) for Sandoz Pharma Ltd..
– Board of Directors of the Genomics Institute of the Novartis Foundation in La Jolla, California.
– Ph.D. in pharmaceutical sciences from the University of Saarbruecken, Germany (1981).

Andreas Rummelt, Ph.D.
– Group Head of Quality Assurance and Technical Operations since 2008 and Member of the Executive Committee since 2006.
– Positions of increasing responsibility in Development at Sandoz Pharma Ltd. (1985).
– Head of Worldwide Technical Research and Development since 1994.
– Head of Technical Operations of the Novartis Pharmaceuticals Division (1999-2004)
– Head of Sandoz (2004-2008).
– Ph.D. in pharmaceutical sciences from the University of Erlangen-Nuernberg, Germany.

Thomas Wellauer, Ph.D.
– Head of Corporate Affairs since 2006 and Member of the Executive Committee since 2007.
– Partner (1991) and Senior Partner (1996) of McKinsey and Company, Switzerland.
– CEO (1997) of the Winterthur Insurance Group, Switzerland, and member of the Group Executive Board when acquired by Credit Suisse.
– Member of the Supervisory Board of Munich RE.
– Ph.D. in systems engineering and M.S. in chemical engineering from the Swiss Federal Institute of Technology in Zurich, Switzerland.
– M.B.A. from the University of Zurich.

Thomas Werlen, Ph.D.
– General Counsel since 2006.
– Member of the Executive Committee since 2008.
– Joined law firm Lenz & Staehelin in Zurich in 1990.
– Joined Cravath, Swaine & Moore in New York in 1995.
– Partner in the London office of Allen & Overy in 2001.
– Ph.D. degree in law from the University of Zurich and master degree in law from Harvard Law School.
– Member of the regulatory board of the SIX Swiss Exchange AG.

David Epstein
– Head of Oncology and Molecular Diagnostics and Permanent attendee of the Executive Committee since 2008.
– Associate in the Strategy Practice of the consulting firm Booz Allen Hamilton in the United States.
– Leadership positions of increasing responsibility in Sandoz since 1989.
– Chief Operating Officer of Novartis Pharmaceuticals Corporation in the U.S. and Head of Novartis Specialty Medicines.
– B.S. in pharmacy from Rutgers University College of Pharmacy (1984) and M.B.A. in finance and marketing from the Columbia University Graduate School of Business (1987).

Jeff George
– CEO of the Sandoz Division and Permanent attendee of the Executive Committee of Novartis since 2008.
– Head of Commercial Operations for Western and Eastern Europe in the Vaccines Division in 2007.
– Head of Emerging Markets for the Middle East, Africa, Southeast Asia and CIS at Novartis Pharma.
– Senior Director of Strategy and Business Development at Gap Inc. in San Francisco, and McKinsey and Company in San Francisco (2001-2004).
– M.A. from the Johns Hopkins University‘s School of Advanced International Studies (1999).
– M.B.A. from Harvard University (2001).

George Gunn
– Member of the Royal College of Veterinary Surgeons.
– Head of Novartis Animal Health, North America (2003).
– Head of the Novartis Animal Health Business Unit since 2004.
– CEO of the Novartis Consumer Health Division and Permanent attendee of the Executive Committee since 2008.
– President of Pharmacia Animal Health, based in the United States.
– Positions of increasing responsibility in healthcare companies for more than 15 years.
– Bachelor of veterinary medicine and surgery degree and a diploma in veterinary state medicine from the Royal (Dick) School of Veterinary Studies in Edinburgh, UK (1973).
– Honorary doctorate in veterinary medicine and surgery from the University of Edinburgh (2008).

Andrin Oswald, M.D.
– CEO of the Novartis Vaccines and Diagnostics Division and Permanent attendee of the Executive Committee since 2008.
McKinsey and Company, Switzerland.
– Head of the Country Pharma Organization.
– M.D. from the University of Geneva, Switzerland, in 1999.
– Delegate of the International Committee of the Red Cross to Nepal (2002-2003).

Former Members

Douglas G. Watson
– President and CEO of Novartis Corporation (1996-1999).
– President of Ciba-Geigy Pharmaceuticals (1986-1996).
– Senior Vice President of Planning at Ciba US Pharmaceuticals (1981-1986).
– Numerous positions within Geigy (1966-1971) and Ciba-Geigy (1971-1981).
– Board of directors for Engelhard Corporation (1991-2006).
– Founding CEO of Pittencrieff Glen Associates.
– Board chairman of LogonHealth Corporation, Javelin Pharmaceuticals Inc., and OraSure Technologies.
– Board of directors for Dendreon Corporation, ValiGen NV, InforMedix Inc., Summit Bancorp, Dendreon Corporation, ValiGen Corporation, Principia Pharmaceuticals Corporation, BZL Biologics Inc., and BioMimetic Pharmaceuticals Inc.
– President’s Advisory Board of Drew University.
– Vice Chairman and Lead Director of Genta Inc.
– Director of Dendreon Corporation.
– Active member of America’s Promise.
– Chairman of the Freedom House Foundation.
Chartered Institute of Management Accountants.
Pharmaceutical Research and Manufacturers of America.

Paul J. Sekhri
– Senior vice president and head of Global Search and Evaluation, Business Development and Licensing for Novartis Pharma AG (1999-2003).
– Head of TPG Biotech since January 2009.
– Board of Directors for ARYx Therapeutics, A.P.T. Pharmaceuticals, and KAI Pharmaceuticals.
– Advisory Board for The BioExec Institute Inc. and advisor to the Brookings Global Health Financing Initiative.
– Board member of the Irvington Institute for Immunological Research, and joined Cancer Research Institute board in October 2007 when the two organizations merged.
– Founder, president and chief executive officer of Cerimon Pharmaceuticals (2004-2008).
– President and chief business officer of ARIAD Pharmaceuticals Inc. (2003-2004).
– Partner for healthcare technology investments in the Sprout Group, the venture affiliate of Credit Suisse First Boston in New York (2002-2003).
– Management positions at Millipore Corporation, PerSeptive Biosystems Inc., Zymark Corporation, and Northeast Consulting Resources Inc.
– B.S. in Zoology and graduate work in neuroscience at the University of Maryland.

Argeris N. (“Jerry”) Karabelas, PhD
– Head of Healthcare and CEO of worldwide Pharmaceuticals for Novartis AG (1998-2000).
– Founder and Chairman of the Novartis Bio Venture Fund (2000-2001).
– Board of Directors of Inotek Pharmaceuticals, Human Genome Sciences, SkyePharma Plc, Anadys Cyreniac Pharmaceutical Inc., Minster Pharmaceuticals plc, and Renovo.
– Chairman of Vanda Pharmaceuticals and Nitromed Inc.
– Member of the Scientific Advisory Council of the Massachusetts General Hospital, and the Visiting Committee for Health Sciences and Technology at Massachusetts Institute of Technology.
– Trustee of Fox Chase Cancer Center and the Philadelphia University of the Sciences.
– Partner at Care Capital LLC since 2001.
– Executive Vice President Pharmaceuticals (1997-1998), President North American Pharmaceuticals (1993-1997) and Vice President of U.S. Marketing (1990-1993) at SmithKline Beecham.
– Ph.D. in pharmacokinetics from the Massachusetts College of Pharmacy.

Dr. Christine T. Fischette
– Executive Director and Head of Negotiation, Global Business Development and Licensing for various therapeutic Business Franchise Boards at Novartis Pharmaceuticals (1999-2007).
– President of Enzo Therapeutics Inc. since 2008, Enzo Biochem Inc.
– Positions of increasing responsibility at Pfizer Pharmaceuticals, directed preclinical/clinical development, medical marketing, and head of Pfizer‘s US commercial arm for diabetes (1987-1999).
– Senior Scientist at Hoffmann-La Roche Inc.
– Post-Doctoral Fellow at Rockefeller University.
– Ph.D. in Physiology from the University of Medicine & Dentistry of New Jersey and B.A. in Biology Education from Rutgers University (1973).